Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Ascendis Pharma A/S (ASND) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Ascendis Pharma A/S is one of 1071 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. ...

Ascendis Pharma A/S (ASND) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Timothy Lee - IR Jan Mikkelsen - President and CEO Scott Smith - EVP and CFO Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Li Watsek - Cantor David Lebowitz - Citi Joseph Schwartz - Leerink Partners Derek Archila - Wells Fargo Kelly Shi - Jefferies Paul Choi - Goldman Sachs Andreas Argyrides - Wedbush Leland Gershell - Oppenheimer Operator Good day, and thank you ...

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details: EventOppenheimer 34th Annual Healthcare Life Sciences ConferenceLocationVirtualDateTuesday, February 13, 2024Time4:00 p.m. Eastern Time / 1:00 p.m. Pacific Time A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at investors.asce ...

Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results – Launch of TransConTM PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024 – TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024 – Total Q4 revenue of €138 million including SKYTROFA® revenue of €64 million; Q4 operating expenses of €155 million – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, February 7, 2024 (GLOBE NEWSWIRE) – Asc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Investors are always looking for stocks that are poised to beat at earnings season and Ascendis Pharma A/S (ASND) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Ascendis Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a prett ...

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and webcast on February 7, 2024, at 4:30 p.m. Eastern Time (ET) to discuss 2023 financial results. Those who would like to participate may access the live webcast here, or register in advance for the ...

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria. YORVIPATH is the second product developed with Ascendis Pharma's TransCon technology platform to be launched commercially. "We are pleased to initiate the launch of YORVIPATH to add ...

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology product ...